Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of Enicepatide in Participants With Overweight or Obesity and Cardiovascular Disease
NCT07918846 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-Blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of Enicepatide in Participants With Overweight or Obesity and Cardiovascular Disease
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- January 6, 2027
- Completion date
- April 17, 2031
- Enrollment
- 8,200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular disease, obesity, overweight
Lead sponsor's other trials
Hoffmann-La Roche, most recent start first.
+2,095 more trials See the organization page
Similar trials
Same condition (Obesity) and phase, most recent start first.
+490 more trials See the condition page